European pharma body criticises SPC waiver vote

The European Federation of Pharmaceutical Industries and Associations ( EFPIA) has sharply criticised an opinion on supplementary protection certificate (SPC) proposals that was issued by a European Parliament committee.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

EU pharma body welcomes president-elect’s mission letter

11 September 2019 European Federation of Pharmaceutical Industries and Associations has welcomed a mission letter from the EU president-elect, which promises to invest in new health sector technologies, promote healthy lifestyles and forge better cooperation within the EU.

Big Pharma

EU committee approves SPC waiver

24 January 2019 The Legal Committee of the European Parliament has voted in favour of the proposed supplementary protection certificate waiver.

Big Pharma

EFPIA concerned over SPC waiver amendments

30 November 2018 Proposed amendments to the EU’s supplementary protection certificate manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

European pharma body criticises SPC waiver vote

More on this story

Editor's picks

Editor's picks

More features